ImpediMed Limited (ASX:IPD) has announced the US FDA has issued it with market clearance for its SOZOTM product.
SOZOTM is a connected platform that monitors fluid levels in heart failure patients, and is used under the direction of a physician in the clinic or home environments.
The clearance is another important regulatory milestone for the business, as it looks to provide a new model of care for cancer and heart failure patients.
Studies involving the use of SOZOTM technology have demonstrated detectable differences in whole-body extra-cellular fluid as low as 0.1 litres.
ImpediMed Limited (ASX:IPD) was trading around 5.91% higher this morning at $0.98